Geode Capital Management’s AC Immune ACIU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $147K | Sell |
61,854
-1,747
| -3% | -$4.81K | ﹤0.01% | 4010 |
|
|
2026
Q1 | $175K | Hold |
63,601
| – | – | ﹤0.01% | 3958 |
|
|
2025
Q4 | $200K | Hold |
63,601
| – | – | ﹤0.01% | 3906 |
|
|
2025
Q3 | $184K | Hold |
63,601
| – | – | ﹤0.01% | 3948 |
|
|
2025
Q2 | $129K | Sell |
63,601
-489
| -0.8% | -$851 | ﹤0.01% | 4000 |
|
|
2025
Q1 | $120K | Hold |
64,090
| – | – | ﹤0.01% | 3990 |
|
|
2024
Q4 | $173K | Buy |
64,090
+5,794
| +10% | +$18.1K | ﹤0.01% | 3947 |
|
|
2024
Q3 | $220K | Buy |
58,296
+3,499
| +6% | +$12.2K | ﹤0.01% | 3868 |
|
|
2024
Q2 | $219K | Hold |
54,797
| – | – | ﹤0.01% | 3875 |
|
|
2024
Q1 | $162K | Buy |
54,797
+13,883
| +34% | +$49.8K | ﹤0.01% | 4006 |
|
|
2023
Q4 | $205K | Hold |
40,914
| – | – | ﹤0.01% | 3936 |
|
|
2023
Q3 | $117K | Buy |
40,914
+3,796
| +10% | +$11.6K | ﹤0.01% | 4191 |
|
|
2023
Q2 | $110K | Hold |
37,118
| – | – | ﹤0.01% | 4299 |
|
|
2023
Q1 | $86.9K | Hold |
37,118
| – | – | ﹤0.01% | 4390 |
|
|
2022
Q4 | $75K | Hold |
37,118
| – | – | ﹤0.01% | 4488 |
|
|
2022
Q3 | $117K | Hold |
37,118
| – | – | ﹤0.01% | 4498 |
|
|
2022
Q2 | $133K | Hold |
37,118
| – | – | ﹤0.01% | 4464 |
|
|
2022
Q1 | $148K | Hold |
37,118
| – | – | ﹤0.01% | 4513 |
|
|
2021
Q4 | $183K | Hold |
37,118
| – | – | ﹤0.01% | 4514 |
|
|
2021
Q3 | $249K | Hold |
37,118
| – | – | ﹤0.01% | 4345 |
|
|
2021
Q2 | $294K | Buy |
37,118
+1,650
| +5% | +$11.4K | ﹤0.01% | 4171 |
|
|
2021
Q1 | $269K | Buy |
35,468
+12,143
| +52% | +$86.7K | ﹤0.01% | 4023 |
|
|
2020
Q4 | $120K | Sell |
23,325
-21,005
| -47% | -$107K | ﹤0.01% | 4017 |
|
|
2020
Q3 | $216K | Buy |
44,330
+4,105
| +10% | +$29.5K | ﹤0.01% | 3692 |
|
|
2020
Q2 | $270K | Sell |
40,225
-2,861
| -7% | -$20.8K | ﹤0.01% | 3576 |
|
|
2020
Q1 | $297K | Buy |
43,086
+10,787
| +33% | +$84.3K | ﹤0.01% | 3432 |
|
|
2019
Q4 | $275K | Sell |
32,299
-20,617
| -39% | -$137K | ﹤0.01% | 3701 |
|
|
2019
Q3 | $261K | Sell |
52,916
-496
| -0.9% | -$2.66K | ﹤0.01% | 3686 |
|
|
2019
Q2 | $296K | Buy |
53,412
+248
| +0.5% | +$1.26K | ﹤0.01% | 3658 |
|
|
2019
Q1 | $268K | Buy |
53,164
+930
| +2% | +$5.92K | ﹤0.01% | 3650 |
|
|
2018
Q4 | $493K | Sell |
52,234
-1,261
| -2% | -$11.9K | ﹤0.01% | 3382 |
|
|
2018
Q3 | $427K | Buy |
53,495
+2,047
| +4% | +$20.6K | ﹤0.01% | 3523 |
|
|
2018
Q2 | $478K | Buy |
51,448
+6,260
| +14% | +$61.9K | ﹤0.01% | 3458 |
|
|
2018
Q1 | $467K | Buy |
45,188
+1,120
| +3% | +$13.6K | ﹤0.01% | 3420 |
|
|
2017
Q4 | $564K | Buy |
44,068
+1,216
| +3% | +$14.3K | ﹤0.01% | 3309 |
|
|
2017
Q3 | $484K | Buy |
42,852
+16,899
| +65% | +$145K | ﹤0.01% | 3368 |
|
|
2017
Q2 | $228K | Sell |
25,953
-6,583
| -20% | -$61K | ﹤0.01% | 3636 |
|
|
2017
Q1 | $337K | Buy |
32,536
+7,152
| +28% | +$87.8K | ﹤0.01% | 3466 |
|
|
2016
Q4 | $329K | Buy |
25,384
+4,094
| +19% | +$56.7K | ﹤0.01% | 3420 |
|
|
2016
Q3 | $350K | Buy |
+21,290
| New | +$368K | ﹤0.01% | 3390 |
|
Other funds holding ACIU
Geode Capital Management's ACIU Position: Q2 2026 in Review
Geode Capital Management reduced its AC Immune (ACIU) stake by 2.7% in Q2 2026, selling an estimated $4.81K and leaving 61,854 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #4010.
Geode Capital Management first reported a position in ACIU in Q3 2016 and has held it in 40 quarters since. The position peaked at $564K in Q4 2017. 36 funds tracked by Wall St. Rank hold ACIU as of Q2 2026.
- Geode Capital Management held 61,854 shares of AC Immune worth $147K as of Q2 2026.
- Geode Capital Management sold 1,747 AC Immune shares in Q2 2026, an estimated $4.81K.
- AC Immune made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4010 holding.
- Geode Capital Management first reported a position in AC Immune in Q3 2016 and has held it in 40 quarters since.
- Geode Capital Management's AC Immune position peaked at $564K in Q4 2017.
- 36 funds tracked by Wall St. Rank held AC Immune as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.